Rinvoq Approved for Active Ankylosing Spondylitis
The Food and Drug Administration (FDA) has approved Rinvoq® (upadacitinib) for the treatment of adults with active ankylosing spondylitis (AS) who have had an inadequate response or intolerance to 1 or more tumor necrosis factor…